AbbVie (ABBV) posted better-than-expected financials for Q4 2025 as the company’s former best seller, Humira, exceeded Street forecasts, offsetting a mixed performance from its newer immunology drugs, Rinvoq and Skyrizi.
The company reported $16.6B in revenue for the quarter with ~10% YoY growth, exceeding the consensus by $200M, as its Humira net revenue reached $1.2B compared to $993.8M projected by analysts, according to Bloomberg data.
Meanwhile, Rinvoq and Skyrizi added $2.37B and $5.00B to the topline with ~30% YoY and ~33% YoY growth, respectively, compared to $2.38B and $4.9B in the consensus, while Humira sales dropped ~26% amid generic competition.
Therapeutic and cosmetic versions of its anti-wrinkle product, Botox, generated $990M and $717M with ~13% YoY and ~4% YoY growth, respectively, while cancer therapy Imbruvica added $671M to the topline, missing $705.3M in the consensus.
For the full year, the company recorded $61.6B in net revenue with ~9% YoY growth, while its adjusted diluted EPS slipped ~1% YoY to $10.00 amid a $2.76 impact related to acquired R&D and other expenses.
During the quarter, ABBV’s adjusted gross and operating margins reached 83.6% and 38.3%, respectively, in comparison to 83.8% and 34.7% in the prior year period. Meanwhile, its adjusted diluted EPS stood at $2.71 in Q4 with ~26% YoY growth, and for 2026, the company projected $14.37 – $14.57 of adjusted EPS, beating $14.22 in the consensus.